I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Omega Diagnostics Gp (ODX)

Omega Diagnostics Gp

Result of General Meeting
RNS Number : 6912S
Omega Diagnostics Group PLC
10 July 2020
 

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Result of General Meeting

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces, further to the announcement of 19 June 2020, the passing of the Resolutions at the General Meeting held earlier today. The Placing, Subscription and Open Offer remain conditional on Admission of the New Ordinary Shares to AIM which is expected to take place at 8.00 a.m. Monday 13 July 2020.

 

Voting details

The vote for Resolution 1 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 1 as contained in the Notice be passed as an Ordinary Resolution.

 

The vote for Resolution 2 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 2 as contained in the Notice be passed as a Special Resolution.

 

Total Voting Rights

With effect from Admission the Company will have 178,153,110 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

 

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 19 June 2020.

 

 

 

For further information, please contact:

 

Omega Diagnostics Group PLC 

Tel: 01259 763 030

Colin King, Chief Executive 

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director




finnCap Ltd   

Tel: 020 7220 0500

Geoff Nash / Hannah Boros / Teddy Whiley (Corporate Finance)


Camille Gochez (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or  omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Colin King

2.

Reason for notification

b)

Position / status

CEO

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Placing

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

50,000

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Kieron Harbinson

2.

Reason for notification

b)

Position / status

CFO

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Subscription and Open Offer

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

35,914

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Jag Grewal

2.

Reason for notification

b)

Position / status

Commercial Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Placing

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

22,500

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1.

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Jeremy Millard

2.

Reason for notification

b)

Position / status

Non-Executive Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

 

ordinary shares of 4p each

 

 

GB00B1VCP282

b)

Nature of the transaction

Acquisition of shares pursuant to the Subscription

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.40

25,000

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

13 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMBBLFFBDLLBBF
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close